{"id":18748,"date":"2022-09-02T17:25:11","date_gmt":"2022-09-02T11:55:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18748"},"modified":"2022-09-29T11:43:25","modified_gmt":"2022-09-29T06:13:25","slug":"primary-sclerosing-cholangitis-treatment-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market","title":{"rendered":"Novel Insights of Primary Sclerosing Cholangitis Treatment Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d69318665f3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d69318665f3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market\/#Current_primary_sclerosing_cholangitis_treatment_landscape_Complicated\" >Current primary sclerosing cholangitis treatment landscape: Complicated<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market\/#Cilofexor_A_potential_first-approved_primary_sclerosing_cholangitis_drug\" >Cilofexor: A potential first-approved primary sclerosing cholangitis drug<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market\/#The_primary_sclerosing_cholangitis_treatment_market_is_all_set_to_grow_significantly\" >The primary sclerosing cholangitis treatment market is all set to grow significantly<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>There are a few major unmet needs in the primary sclerosing cholangitis (PSC) treatment market, which include a lack of effective therapies, proven surveillance strategies, tools for early detection of malignancies, impact on quality of life (QoL), and surrogate endpoints in primary sclerosing cholangitis clinical trials.<\/p>\n\n\n\n<p>Although a rare disease, primary sclerosing cholangitis still affects around <strong>30,000<\/strong> people in the US, <strong>21,000<\/strong> in the EU5, <strong>9,000<\/strong> in Nordic countries, and another <strong>1,200<\/strong> in Japan in 2021. As per DelveInsight\u2019s estimates, the overall <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-epidemiology-forecast\">primary sclerosing cholangitis prevalence<\/a> in both genders is subject to increase in the coming years and reach up to approximately <strong>29,000<\/strong> and <strong>11,000<\/strong> cases by 2032 in males and females, respectively.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-2b3e32b9-1e77-48a0-a342-d8a731ad52a6\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.2.1<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-70wjsdh-994-\"><rect fill=\"none\" height=\"271\" width=\"431\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-70wjsdh-999-\"><rect fill=\"none\" height=\"271\" width=\"431\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-70wjsdh-1000-\"><rect fill=\"none\" height=\"271\" width=\"431\" x=\"68\" y=\"92\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"271\" width=\"431\" x=\"68\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 175.5 92 L 175.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 283.5 92 L 283.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 390.5 92 L 390.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 92 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 67.5 92 L 67.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 68 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 295.5 L 499 295.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 228.5 L 499 228.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 160.5 L 499 160.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 91.5 L 499 91.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"271\" width=\"431\" x=\"68\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 68 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.44443416595459 227.5)\" x=\"26.44443416595459\" y=\"227.5\">Total diagnosed cases<\/text><path class=\"highcharts-axis-line\" d=\"M 68 92 L 68 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-70wjsdh-999-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(68,92) scale(1 1)\"><rect aria-label=\"US, 30. Total diagnosed prevalent cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"203\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"52\" x=\"27.5\" y=\"68.5\"><\/rect><rect aria-label=\"EU5, 21. Total diagnosed prevalent cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"142\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"52\" x=\"135.5\" y=\"129.5\"><\/rect><rect aria-label=\"Nordic countries, 9. Total diagnosed prevalent cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"61\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"52\" x=\"243.5\" y=\"210.5\"><\/rect><rect aria-label=\"Japan, 1.2. Total diagnosed prevalent cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"8\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"52\" x=\"350.5\" y=\"263.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(68,92) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Primary Sclerosing Cholangitis Epidemiological<tspan dy=\"21\" x=\"255\">\u200b<\/tspan>Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"73\">Total Diagnosed Prevalent Cases in the 7MM + Nordic Countries<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(68,92) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(41,45)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">30<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>30<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(149,106)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">21<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>21<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(260,187)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">9<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>9<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(363,240)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">1.2<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>1.2<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"121.875\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"229.625\" y=\"382\">EU5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"337.375\" y=\"382\">Nordic countries<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"445.125\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"299\">10<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"232\">20<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"164\">30<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"96\">40<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Primary Sclerosing Cholangitis Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Primary Sclerosing Cholangitis Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-70wjsdh-1000-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Primary Sclerosing Cholangitis Epidemiological Insights\"},\"subtitle\":{\"text\":\"Total Diagnosed Prevalent Cases in the 7MM + Nordic Countries\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Total diagnosed prevalent cases (in thousands)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Total diagnosed prevalent cases (in thousands)\\\"\\n\\\"US\\\";30\\n\\\"EU5\\\";21\\n\\\"Nordic countries\\\";9\\n\\\"Japan\\\";1.2\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Total diagnosed cases \"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Primary Sclerosing Cholangitis Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-epidemiology-forecast\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-2b3e32b9-1e77-48a0-a342-d8a731ad52a6\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Moreover, according to the <strong>American College of Gastroenterology<\/strong>, <strong>70%<\/strong> of primary sclerosing cholangitis patients are men, with an average age of <strong>40<\/strong> at primary sclerosing cholangitis diagnosis. Inflammatory bowel disease affects up to <strong>90%<\/strong> of primary sclerosing cholangitis patients. The more common of the two types of inflammatory bowel disease, ulcerative colitis, affects approximately <strong>87%<\/strong> of primary sclerosing cholangitis patients, while Crohn's disease affects the remaining <strong>13%<\/strong>. In contrast, primary sclerosing cholangitis affects only<strong> 4%<\/strong> of all <a href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-bowel-disease-market\">patients with inflammatory bowel disease<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-primary-sclerosing-cholangitis-treatment-landscape-complicated\"><span class=\"ez-toc-section\" id=\"Current_primary_sclerosing_cholangitis_treatment_landscape_Complicated\"><\/span><strong>Current primary sclerosing cholangitis treatment landscape: Complicated<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Unfortunately, there are no disease-specific approved therapies for primary sclerosing cholangitis treatment. High-dose ursodeoxycholic acid is used for primary sclerosing cholangitis treatment for patients because there is a trend toward increased survival. Dominant bile duct stenosis should be treated endoscopically. However, liver transplantation continues to be the only primary sclerosing cholangitis treatment option for patients with advanced disease. Moreover, ursodeoxycholic acid primary sclerosing cholangitis treatment improves abnormal biochemical tests. It works by increasing the bile flow and preventing liver cell damage, but it does not appear to affect survival or the need for liver transplantation. Additionally, studies have shown that it may be harmful in high dosages.<\/p>\n\n\n\n<p>Besides this, immunosuppressive-based <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-pipeline-insight\">primary sclerosing cholangitis therapies<\/a> such as <strong>glucocorticoids, azathioprine, tacrolimus<\/strong>, and a few others are in use for primary sclerosing cholangitis treatment, especially in PSC patients with additional autoimmune hepatitis (AIH) or IgG4-related sclerosing cholangitis (IgG4-SC).&nbsp;<\/p>\n\n\n\n<p>Although the only intervention, which extends the survival of PSC patients, liver transplantation is costly and invasive. Recurrent primary sclerosing cholangitis (rPSC) is an enduring clinical dilemma. It occurs in <strong>1.8\u201336.8%<\/strong> of liver transplantation recipients and is associated with a greater need for repeated liver transplantation, a fourfold increased risk of death, and decreased overall survival compared to PSC patients who remain rPSC-free.<\/p>\n\n\n\n<p>Hence, there is an urgent unmet need for a safe and effective primary sclerosing cholangitis therapy that addresses the underlying cause of this multifaceted disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cilofexor_A_potential_first-approved_primary_sclerosing_cholangitis_drug\"><\/span><strong>Cilofexor: A potential first-approved primary sclerosing cholangitis drug<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-market\">primary sclerosing cholangitis market size<\/a> was valued at ~USD 800 million in 2019 and is projected to reach approximately USD 3,600 million by 2032, at a CAGR of 12%, as per DelveInsight\u2019s estimates. <\/strong><\/p><\/blockquote>\n\n\n\n<p>The major market players in the primary sclerosing cholangitis treatment market are <strong>Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics<\/strong>, among others.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141845\/Key-Companies-in-the-Primary-Sclerosing-Cholangitis-Market-1024x285.png\" alt=\"primary sclerosing cholangitis companies\" class=\"wp-image-18751\" width=\"1024\" height=\"285\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141845\/Key-Companies-in-the-Primary-Sclerosing-Cholangitis-Market-1024x285.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141845\/Key-Companies-in-the-Primary-Sclerosing-Cholangitis-Market-300x83.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141845\/Key-Companies-in-the-Primary-Sclerosing-Cholangitis-Market-150x42.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141845\/Key-Companies-in-the-Primary-Sclerosing-Cholangitis-Market-768x214.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141845\/Key-Companies-in-the-Primary-Sclerosing-Cholangitis-Market.png 1097w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Leading Players Developing Therapies for Primary Sclerosing Cholangitis Treatment<\/strong><\/figcaption><\/figure>\n\n\n\n<p>There is a list of late-stage assets with distinct MoA being developed for treating PSC patients and are expected to enter the primary sclerosing cholangitis treatment market of the US, EU5 (Germany, Italy, France, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan in the next few years. Few of the molecules in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-pipeline-insight\">primary sclerosing cholangitis pipeline<\/a> include <strong>cilofexor (Gilead Sciences\/Phenex Pharmaceuticals), Volixibat (Mirum Pharmaceuticals, Inc.), norursodeoxycholic Acid (Dr. Falk Pharma; EA Pharma), and HTD1801 (HighTide Biopharma),<\/strong> among others.<\/p>\n\n\n\n<p><strong>Cilofexor (Gilead Sciences\/Phenex Pharmaceuticals) <\/strong>is a potent, selective, and orally active nonsteroidal FXR agonist. It is an investigational agent to treat PSC, a chronic cholestatic liver disease with limited primary sclerosing cholangitis treatment options for patients and significant unmet needs. Currently, <strong>cilofexor <\/strong>is undergoing evaluation in the <strong>phase III PRIMIS study<\/strong> to assess the safety, tolerability, and efficacy of cilofexor in non-cirrhotic subjects with primary sclerosing cholangitis at multiple locations worldwide. It is expected to enter the US primary sclerosing cholangitis treatment market by <strong>2025<\/strong>.&nbsp;<\/p>\n\n\n\n<p>While <strong>norursodeoxycholic acid (norUDCA)<\/strong> is a side-chain-shortened derivative of ursodeoxycholic acid with relative resistance to amidation, which enables its cholehepatic shunting. Based on pharmacologic properties, it is a promising primary sclerosing cholangitis drug for a range of cholestatic liver and bile duct disorders. Recently, it has been successfully clinically tested in <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-epidemiology-forecast\">PSC patients<\/a>. Moreover, hepatic enrichment of norUDCA facilitates direct therapeutic effects on both parenchymal and non-parenchymal liver cells, thereby counteracting cholestasis, steatosis, hepatic inflammation, and fibrosis, inhibiting hepatocellular proliferation, and promoting autophagy.<\/p>\n\n\n\n<p>Another surging asset set to compete in the primary sclerosing cholangitis treatment market is <strong>HTD1801<\/strong>. It is a first-in-class new molecular entity and is an ionic salt of two active moieties: berberine and ursodeoxycholic acid. It is administered orally, acts as a lipid modulator, and significantly reduces liver fat. It has completed a <strong>phase II <\/strong>primary sclerosing cholangitis clinical trial to treat PSC and is currently under <strong>phase II trials<\/strong> for other chronic disorders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_primary_sclerosing_cholangitis_treatment_market_is_all_set_to_grow_significantly\"><\/span><strong>The primary sclerosing cholangitis treatment market is all set to grow significantly<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As there is no approved therapy, the first drug approved in the primary sclerosing cholangitis market will have a competitive advantage. Several major pharmaceutical companies are actively working on developing a novel drug for primary sclerosing cholangitis treatment. As a result, the development of disease-specific primary sclerosing cholangitis therapies will augur well for the primary sclerosing cholangitis treatment market landscape, which, in turn, will facilitate significant changes during the forecast period (2019\u20132032).&nbsp;<\/p>\n\n\n\n<p>With an improved primary sclerosing cholangitis diagnosis and safe and efficacious treatment options, the primary sclerosing cholangitis treatment market is expected to grow significantly. Furthermore, the rising prevalence of primary sclerosing cholangitis in conjunction with an increase in inflammatory bowel disease, ulcerative colitis, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\">crohn's disease<\/a> is also propelling the primary sclerosing cholangitis treatment market forward.<\/p>\n\n\n\n<p>However, the easy availability of off-label therapies will reduce the primary sclerosing cholangitis market share of newly approved drugs. Targeted health policies are required to meet patients' needs and expectations. Moreover, there is a lack of prognostic and predictive biomarkers to understand disease progression and identify complications caused by fibrosis. Furthermore, there is no curative therapy available; <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-market\">primary sclerosing cholangitis treatment<\/a> is limited to symptom management.<\/p>\n\n\n\n<p>Nevertheless, pricing and reimbursement challenges, along with associated long-term side effects of approved therapies, are two major factors that influence the primary sclerosing cholangitis treatment market success of the upcoming therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-sclerosing-cholangitis-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-1024x256.jpg\" alt=\"primary sclerosing cholangitis treatment market\" class=\"wp-image-18750\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-1024x256.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-300x75.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-150x38.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-768x192.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-1536x384.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market-1568x392.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02141735\/primary-sclerosing-cholangitis-treatment-market.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1662108100405\"><strong class=\"schema-faq-question\"><strong>1. What is primary sclerosing cholangitis?<\/strong><\/strong> <p class=\"schema-faq-answer\">A chronic condition called primary sclerosing cholangitis (PSC) steadily deteriorates the bile ducts. Due to inflammation, scarring, or fibrosis, the bile ducts get blocked in PSC patients, causing a buildup of bile in the liver that eventually kills liver cells and results in cirrhosis or liver fibrosis. The liver gradually loses its capacity as cirrhosis advances and the quantity of scar tissue increases. The scar tissue may obstruct the bile ducts' ability to drain, resulting in bile infection.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108112209\"><strong class=\"schema-faq-question\"><strong>2. How many primary sclerosing cholangitis types are there?<\/strong><\/strong> <p class=\"schema-faq-answer\">The primary sclerosing cholangitis types are classified into subgroups: classic primary sclerosing cholangitis, small duct primary sclerosing cholangitis, and primary sclerosing cholangitis associated with autoimmune hepatitis.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108121064\"><strong class=\"schema-faq-question\"><strong>3. What are the symptoms of primary sclerosing cholangitis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Fatigue, abdominal discomfort, itching (pruritus), and obstructive jaundice are common initial primary sclerosing cholangitis symptoms. Malaise, abdominal pain, nausea, dark urine, light-colored stools, unintended weight loss, and\/or hepatomegaly and\/or splenomegaly are additional primary sclerosing cholangitis symptoms.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108132770\"><strong class=\"schema-faq-question\"><strong>4. How is primary sclerosing cholangitis diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">The evaluation of patient history, clinical features, liver function tests (ALP, GT, ALT, bilirubin, albumin), blood tests, and the exclusion of differential diagnoses all contribute to the primary sclerosing cholangitis diagnosis. Ultrasonography, ERCP, MRCP, MRC, and ultrasound are also used for hepatobiliary system imaging. A liver biopsy is occasionally required.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108143001\"><strong class=\"schema-faq-question\"><strong>5. What are the current primary sclerosing cholangitis treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">Despite several decades of primary sclerosing cholangitis clinical trials of numerous pharmacotherapies, safe and effective medical therapy has yet to be established. The primary sclerosing cholangitis treatment focuses on the specific symptoms that each person experiences, as well as slowing the disorder's progression. High-dose ursodeoxycholic acid (UDCA) is currently being used for primary sclerosing cholangitis treatment, and there is a trend toward increased survival. Endoscopic treatment should be used for dominant bile duct stenosis. However, for patients with advanced disease, liver transplantation remains the only primary sclerosing cholangitis treatment option.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108155334\"><strong class=\"schema-faq-question\"><strong>6. What are the primary sclerosing cholangitis causes?<\/strong><\/strong> <p class=\"schema-faq-answer\">The primary sclerosing cholangitis causes are unknown. The immune system response to an infection or toxin may cause the disease in persons who are genetically prone to it. Without a liver transplant, the primary sclerosing cholangitis life expectancy is roughly 10 years.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108166797\"><strong class=\"schema-faq-question\"><strong>7. Which players are active in the primary sclerosing cholangitis market?<\/strong><\/strong> <p class=\"schema-faq-answer\">The major market players in the primary sclerosing cholangitis treatment market are Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, among others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662108180832\"><strong class=\"schema-faq-question\"><strong>8. How is the primary sclerosing cholangitis pipeline looks like?<\/strong><\/strong> <p class=\"schema-faq-answer\">Few of the molecules in the primary sclerosing cholangitis pipeline include cilofexor (Gilead Sciences\/Phenex Pharmaceuticals), Volixibat (Mirum Pharmaceuticals, Inc.), norursodeoxycholic Acid (Dr. Falk Pharma; EA Pharma), and HTD1801 (HighTide Biopharma), among others.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>There are a few major unmet needs in the primary sclerosing cholangitis (PSC) treatment market, which include a lack of effective therapies, proven surveillance strategies, tools for early detection of malignancies, impact on quality of life (QoL), and surrogate endpoints in primary sclerosing cholangitis clinical trials. Although a rare disease, primary sclerosing cholangitis still affects [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":18754,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2617,19694,19692,19693,19696,19691,19695],"industry":[17225],"therapeutic_areas":[17239,17234],"class_list":["post-18748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-primary-sclerosing-cholangitis","tag-primary-sclerosing-cholangitis-clinical-trials","tag-primary-sclerosing-cholangitis-market","tag-primary-sclerosing-cholangitis-pipeline","tag-primary-sclerosing-cholangitis-therapies","tag-primary-sclerosing-cholangitis-treatment","tag-psc-patients","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rich Insights into Primary Sclerosing Cholangitis Treatment Market<\/title>\n<meta name=\"description\" content=\"First drug approved in primary sclerosing cholangitis treatment market by companies will have a competitive advantage in therapeutic domain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rich Insights into Primary Sclerosing Cholangitis Treatment Market\" \/>\n<meta property=\"og:description\" content=\"First drug approved in primary sclerosing cholangitis treatment market by companies will have a competitive advantage in therapeutic domain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-02T11:55:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-29T06:13:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02142339\/primary-sclerosing-cholangitis-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rich Insights into Primary Sclerosing Cholangitis Treatment Market","description":"First drug approved in primary sclerosing cholangitis treatment market by companies will have a competitive advantage in therapeutic domain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market","og_locale":"en_US","og_type":"article","og_title":"Rich Insights into Primary Sclerosing Cholangitis Treatment Market","og_description":"First drug approved in primary sclerosing cholangitis treatment market by companies will have a competitive advantage in therapeutic domain.","og_url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-09-02T11:55:11+00:00","article_modified_time":"2022-09-29T06:13:25+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02142339\/primary-sclerosing-cholangitis-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market","url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market","name":"Rich Insights into Primary Sclerosing Cholangitis Treatment Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02142339\/primary-sclerosing-cholangitis-treatment-landscape.png","datePublished":"2022-09-02T11:55:11+00:00","dateModified":"2022-09-29T06:13:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"First drug approved in primary sclerosing cholangitis treatment market by companies will have a competitive advantage in therapeutic domain.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108100405"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108112209"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108121064"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108132770"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108143001"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108155334"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108166797"},{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108180832"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02142339\/primary-sclerosing-cholangitis-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02142339\/primary-sclerosing-cholangitis-treatment-landscape.png","width":772,"height":482,"caption":"primary-sclerosing-cholangitis-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108100405","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108100405","name":"1. What is primary sclerosing cholangitis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"A chronic condition called primary sclerosing cholangitis (PSC) steadily deteriorates the bile ducts. Due to inflammation, scarring, or fibrosis, the bile ducts get blocked in PSC patients, causing a buildup of bile in the liver that eventually kills liver cells and results in cirrhosis or liver fibrosis. The liver gradually loses its capacity as cirrhosis advances and the quantity of scar tissue increases. The scar tissue may obstruct the bile ducts' ability to drain, resulting in bile infection.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108112209","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108112209","name":"2. How many primary sclerosing cholangitis types are there?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The primary sclerosing cholangitis types are classified into subgroups: classic primary sclerosing cholangitis, small duct primary sclerosing cholangitis, and primary sclerosing cholangitis associated with autoimmune hepatitis.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108121064","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108121064","name":"3. What are the symptoms of primary sclerosing cholangitis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Fatigue, abdominal discomfort, itching (pruritus), and obstructive jaundice are common initial primary sclerosing cholangitis symptoms. Malaise, abdominal pain, nausea, dark urine, light-colored stools, unintended weight loss, and\/or hepatomegaly and\/or splenomegaly are additional primary sclerosing cholangitis symptoms.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108132770","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108132770","name":"4. How is primary sclerosing cholangitis diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The evaluation of patient history, clinical features, liver function tests (ALP, GT, ALT, bilirubin, albumin), blood tests, and the exclusion of differential diagnoses all contribute to the primary sclerosing cholangitis diagnosis. Ultrasonography, ERCP, MRCP, MRC, and ultrasound are also used for hepatobiliary system imaging. A liver biopsy is occasionally required.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108143001","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108143001","name":"5. What are the current primary sclerosing cholangitis treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Despite several decades of primary sclerosing cholangitis clinical trials of numerous pharmacotherapies, safe and effective medical therapy has yet to be established. The primary sclerosing cholangitis treatment focuses on the specific symptoms that each person experiences, as well as slowing the disorder's progression. High-dose ursodeoxycholic acid (UDCA) is currently being used for primary sclerosing cholangitis treatment, and there is a trend toward increased survival. Endoscopic treatment should be used for dominant bile duct stenosis. However, for patients with advanced disease, liver transplantation remains the only primary sclerosing cholangitis treatment option.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108155334","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108155334","name":"6. What are the primary sclerosing cholangitis causes?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The primary sclerosing cholangitis causes are unknown. The immune system response to an infection or toxin may cause the disease in persons who are genetically prone to it. Without a liver transplant, the primary sclerosing cholangitis life expectancy is roughly 10 years.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108166797","position":7,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108166797","name":"7. Which players are active in the primary sclerosing cholangitis market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The major market players in the primary sclerosing cholangitis treatment market are Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, among others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108180832","position":8,"url":"https:\/\/www.delveinsight.com\/blog\/primary-sclerosing-cholangitis-treatment-market#faq-question-1662108180832","name":"8. How is the primary sclerosing cholangitis pipeline looks like?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Few of the molecules in the primary sclerosing cholangitis pipeline include cilofexor (Gilead Sciences\/Phenex Pharmaceuticals), Volixibat (Mirum Pharmaceuticals, Inc.), norursodeoxycholic Acid (Dr. Falk Pharma; EA Pharma), and HTD1801 (HighTide Biopharma), among others.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/02142339\/primary-sclerosing-cholangitis-treatment-landscape-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">primary sclerosing cholangitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">primary sclerosing cholangitis clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">primary sclerosing cholangitis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">primary sclerosing cholangitis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">primary sclerosing cholangitis therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">primary sclerosing cholangitis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PSC patients<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">primary sclerosing cholangitis<\/span>","<span class=\"advgb-post-tax-term\">primary sclerosing cholangitis clinical trials<\/span>","<span class=\"advgb-post-tax-term\">primary sclerosing cholangitis market<\/span>","<span class=\"advgb-post-tax-term\">primary sclerosing cholangitis pipeline<\/span>","<span class=\"advgb-post-tax-term\">primary sclerosing cholangitis therapies<\/span>","<span class=\"advgb-post-tax-term\">primary sclerosing cholangitis treatment<\/span>","<span class=\"advgb-post-tax-term\">PSC patients<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Sep 2, 2022","modified":"Updated on Sep 29, 2022"},"absolute_dates_time":{"created":"Posted on Sep 2, 2022 5:25 pm","modified":"Updated on Sep 29, 2022 11:43 am"},"featured_img_caption":"primary-sclerosing-cholangitis-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18748"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18748\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18754"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18748"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18748"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}